App-Quantinova.ai

No Peak of New-onset Inhibitors in the Aging Hemophilia Population: An International, Retrospective, Observational, Cohort Study of New Inhibitors in People with Hemophilia Aged 40 Years and Older (the NIAP Study)

J. Astermark - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Non-redundant Roles of Platelet Glycoprotein VI and IIb/IIIa via Syk Kinase in Fibrin-dependent Thrombus Shielding under Flow

G. Perrella - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

fibrinogen and thrombin

Observational Study of Outcomes in Patients with Antiphospholipid Syndrome Anticoagulated with Rivaroxaban

T.W. Htut - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Antiphospholipid syndrome

rivaroxaban

Oligosymptomatic Thrombosis in a Young Girl with Upshaw-Schulman Syndrome (USS) Not Receiving Prophylactic Plama Infusion

S. Tanabe - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Online Apps Improve Haemostasis Assay Reproducibility and Facilitate Open Data and Code Sharing

C. Longstaff - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Optimisation of Assays for Laboratory Monitoring of Emicizumab in Treated Patients

A.N. McCormick - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Oral Anticoagulation in Elderly Patients with Atrial Fibrillation: The Murcia AF Project Phase II

J.M. Rivera-Caravaca - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Patient Characteristics, Treatment Trends and Patterns

W. Ghanima - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Outcomes of Patients with Anti-Xa versus APTTr Monitoring for Unfractionated Heparin Infusions during Extracorporeal Membrane Oxygenation

A.J. Doyle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Patients Experience of Living with Cancer Associated Thrombosis in Singapore (PELICAN)

E.-S. Yap - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP) Should Be Managed in a Critical Care Setting – A UK Single TTP Referral Centre Experience

R. Shaw - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

N/A

Perioperative Management of Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

K.J. Pasi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Hemostatic Solution

Perioperative Management with Recombinant Factor IX Fc Fusion (rFIXFc): Irish and UK Experience

M. O'Donovan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Personalizing Prophylaxis with Rurioctocog Alfa Pegol in Previously Treated Patients with Severe Hemophilia A: Outcomes from the Phase 3b CONTINUATION and Phase 3 PROPEL Studies

C. Escuriola-Ettingshausen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

rurioctocog alfa

Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism

D. Roeshammar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Pradax

Pharmacokinetic-Pharmacodynamic Relationship between Dabigatran Plasma Concentrations and Coagulation Laboratory Parameters in Paediatric Patients with Venous Thromboembolism

L. Mitchell - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Pradax

Pharmacopeial Potency Equated Sulodexide Produces Comparable Anticoagulation as Studied in Whole Blood

B. Daravath - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

sulodexide

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

A.C. Newland - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Phase I/II, Open-Label, Ongoing Study of PRN1008 (Rilzabrutinib), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients with Heavily Pretreated Immune Thrombocytopenia (ITP)

D. Kuter - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

L-Tyrosine

Phosphoproteomic Fingerprint of Platelets in Obesity: Insights into Platelet Reactivity

M. Nuez Barrachina - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Filters

45280 Abstracts